Medifast Expects Q2 Revenue Of $150M-$170M (Est $175.10M), EPS Of $0.05-$0.40 (Est $0.67)
Portfolio Pulse from Benzinga Newsdesk
Medifast provided its Q2 revenue and EPS guidance, expecting revenues of $150M-$170M, below the estimated $175.10M, and EPS of $0.05-$0.40, under the estimated $0.67. The EPS forecast excludes costs from the LifeMD collaboration and market price changes of its LifeMD stock investment.
April 29, 2024 | 8:45 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Medifast's Q2 revenue and EPS guidance are below analyst expectations, potentially impacting investor sentiment negatively.
Guidance below analyst expectations can lead to negative investor sentiment and potentially decrease stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100